false
zh-CN,zh-TW,en,pt,es
Catalog
Teladoc | Diabetes and Weight Management Part 1
Weight Management Treatment Infographic
Weight Management Treatment Infographic
Back to course
Pdf Summary
The infographic provides an overview of weight management treatment options from the American Diabetes Association’s (ADA) Standards of Care in Diabetes—2023. It outlines behavioral strategies, goal-setting characteristics using the SMART framework (Specific, Measurable, Actionable, Timely, Realistic), and pharmacological agents. <br /><br />Behavioral strategies emphasize diabetes self-management and health behaviors to promote optimal health outcomes. The visual guide highlights goal-setting characteristics as "specific," "measurable," "actionable," "timely," and "realistic," reinforcing the importance of structured objectives for managing weight.<br /><br />Several pharmacological agents are mentioned with their common side effects and safety concerns, including:<br />- **Phentermine**: Short-term treatment associated with dry mouth, insomnia, dizziness, irritability, increased blood pressure, and elevated heart rate. Contraindicated with monoamine oxidase inhibitors.<br />- **Orlistat**: Abdominal pain, flatulence, and fecal urgency. Risks include vitamin malabsorption and severe liver injury.<br />- **Phentermine/Topiramate ER**: Constipation, paresthesia, insomnia. Safety concerns include cognitive impairment and acute angle-closure glaucoma.<br />- **Naltrexone/Bupropion ER**: Constipation, nausea, and headache. Black box warning for suicidal behavior/ideation in those under 24 with depression.<br />- **Liraglutide**: Gastrointestinal issues, esophageal reflux. Linked to pancreatitis and potential thyroid tumors.<br />- **Semaglutide**: Similar to Liraglutide, with gastrointestinal side effects and a black box warning for thyroid tumors.<br /><br />The infographic suggests a person-centered approach and emphasizes the use of SMART goals for lifestyle modifications. For more information on approved obesity pharmacotherapy options, it directs users to Section 8 of ADA’s Standards of Care in Diabetes—2023. Contact information for further inquiries is provided via a phone number and website.<br /><br />For a comprehensive understanding of incretins and weight management in type 2 diabetes, consulting the ADA materials and resources is encouraged.
Keywords
weight management
diabetes
behavioral strategies
SMART goals
pharmacological agents
American Diabetes Association
phentermine
orlistat
liraglutide
semaglutide
American Diabetes Association 2451 Crystal Drive, Suite 900, Arlington, VA 22202
1-800-DIABETES
Follow us on
Copyright All rights reserved.
×